As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

CIL Announces New Hire John Bakke as Vice President of Finance

August 11, 2022

Cambridge Isotope Laboratories, Inc, the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of John Bakke as Vice President of Finance. John reports directly to the CEO, Cliff Caldwell.

John is a leader who brings over 30 years of public and private company experience in a wide range of finance and business functions within various industries, having held several senior-level positions from corporate VP, general manager, controller, and senior financial analyst for both national and global corporations.

Prior to joining CIL, John has most recently been working as a director for Danforth Advisors assisting biotech and pharmaceutical clients to manage and grow their business. Before Danforth, John spent over 22 years with Charles River Laboratories working in various finance roles including many years as a business unit controller followed by 11 years managing Charles River’s Avian Vaccine Service business.

“CIL has experienced tremendous growth the past few years. We are a company filled with experienced employees committed to supporting the scientific discovery and commercialization of isotopes across a broad range of extremely high value applications,” said Cliff Caldwell, CEO. “I am excited to have John join our senior leadership team. John’s experience, financial expertise, and leadership qualities will be a valuable addition to Cambridge Isotopes supporting that growth.”

“I am very pleased and excited to be a member of the CIL team,” adds John, “and I am looking forward to helping CIL achieve its growth objectives for the future.”



About Cambridge Isotope Laboratories, Inc.

CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. 

For more information on CIL, visit

Back to list
CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.